Log In
Print
BCIQ
Print
Print this Print this
 

MKC1106-MT

  Manage Alerts
Collapse Summary General Information
Company MannKind Corp.
DescriptionActive immunotherapy consisting of a DNA plasmid and 2 synthetic peptides administered separately, which target 2 tumor-specific antigens
Molecular Target
Mechanism of ActionImmunotherapy
Latest Stage of DevelopmentPhase II
IndicationMelanoma
Partner

Colby Pharmaceutical Co.
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today